secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001213900-25-004756
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CERO Therapeutics gets Nasdaq Panel extension to April 22, 2025 for listing compliance
--------------------------------------------------------------------------------

- Nasdaq Panel grants extension to regain compliance with $50M MVLS, $15M MVPHS, and $1.00 bid price requirements.
- Company completed 100:1 reverse stock split on Jan 8, 2025; stock closed above $1.00 since then.
- Must apply to transfer to Nasdaq Capital Market by Jan 22, 2025 and meet $2.5M stockholders' equity.
- Equity raised from committed facility and warrant exercises since Sep 30, 2024; additional capital raising planned.
- Company cannot assure success in raising capital or meeting equity requirement by extension date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025004756/0001213900-25-004756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025004756/ea0228123-8k_cerotherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-004756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer